Histone deacetylase inhibitors: a novel target of anticancer therapy (review).

@article{Kouraklis2006HistoneDI,
  title={Histone deacetylase inhibitors: a novel target of anticancer therapy (review).},
  author={Gregorios P. Kouraklis and Stamatios Theocharis},
  journal={Oncology reports},
  year={2006},
  volume={15 2},
  pages={489-94}
}
Accumulating evidence suggests that the acetylation and deacetylation of histones play significant roles in transcriptional regulation of eukaryotic cells. The balance between acetylation and deacetylation is an important factor in regulating gene expression and is thus linked to the control of cell fate. The histone deacetylase inhibitors (HDIs) including the hydroxamic acids, such as suberoylanilide hydroxamic acid and pyroxamide, the benzamides MS-275 and CI-994 and the butyrate derivative 4… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 60 references

Histone deacetylase inhibitors: understanding a new wave of anticancer agents

  • A Garea-Villar, M Steller
  • Int J Cancer
  • 2004
2 Excerpts

Similar Papers

Loading similar papers…